Literature DB >> 21815182

Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study.

John S Welch1, Jeffery M Klco, Feng Gao, Elizabeth Procknow, Geoffery L Uy, Keith E Stockerl-Goldstein, Camille N Abboud, Peter Westervelt, John F DiPersio, Anjum Hassan, Amanda F Cashen, Ravi Vij.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21815182     DOI： 10.1002/ajh.22092

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  17 in total

1.  Is the combinational administration of doxorubicin and glutathione a reasonable proposal?

Authors:  Bo-Yu Shen; Chong Chen; Yang-Fan Xu; Jia-Jia Shen; Hui-Min Guo; Hao-Feng Li; Xi-Nuo Li; Dian Kang; Yu-Hao Shao; Zhang-Pei Zhu; Xiao-Xi Yin; Lin Xie; Guang-Ji Wang; Yan Liang
Journal:  Acta Pharmacol Sin       Date:  2018-09-14       Impact factor: 6.150

2.  Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome.

Authors:  Noël J-M Raynal; Elodie M Da Costa; Justin T Lee; Vazganush Gharibyan; Saira Ahmed; Hanghang Zhang; Takahiro Sato; Gabriel G Malouf; Jean-Pierre J Issa
Journal:  Mol Cancer Ther       Date:  2016-12-15       Impact factor: 6.261

Review 3.  The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapy.

Authors:  Lorenzo Falchi; Srdan Verstovsek; Farhad Ravandi-Kashani; Hagop M Kantarjian
Journal:  Cancer       Date:  2015-12-30       Impact factor: 6.860

4.  Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity.

Authors:  Xiaoyan Wu; Zhenhua Hu; Sara Nizzero; Guodong Zhang; Maricela R Ramirez; Ce Shi; Jin Zhou; Mauro Ferrari; Haifa Shen
Journal:  J Control Release       Date:  2017-10-16       Impact factor: 9.776

5.  A phase II study of arsenic trioxide in patients with relapsed or refractory malignant lymphoma.

Authors:  Hongli Zhao; Guoxun Sun; Desheng Kong; Yujing Zhang; Wudan Shi; Mingming Zhao; Luojia Hong; Zhenkui Qiao
Journal:  Med Oncol       Date:  2015-02-20       Impact factor: 3.064

Review 6.  Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions.

Authors:  Tae Kon Kim; Steven D Gore; Amer M Zeidan
Journal:  Semin Hematol       Date:  2015-04-08       Impact factor: 3.851

Review 7.  Decitabine: a review of its use in older patients with acute myeloid leukaemia.

Authors:  Monique P Curran
Journal:  Drugs Aging       Date:  2013-06       Impact factor: 3.923

8.  A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML.

Authors:  John S Welch; Haixia Niu; Geoffrey L Uy; Peter Westervelt; Camille N Abboud; Ravi Vij; Keith E Stockerl-Goldstein; Meagan Jacoby; Iskra Pusic; Mark A Schroeder; John F Dipersio; Amanda F Cashen
Journal:  Am J Hematol       Date:  2014-04-28       Impact factor: 10.047

9.  Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9.

Authors:  David Chau; Karen Ng; Thomas Sau-Yan Chan; Yuen-Yee Cheng; Bonnie Fong; Sidney Tam; Yok-Lam Kwong; Eric Tse
Journal:  J Hematol Oncol       Date:  2015-05-08       Impact factor: 17.388

Review 10.  The role of autophagy in targeted therapy for acute myeloid leukemia.

Authors:  Wenxin Du; Aixiao Xu; Yunpeng Huang; Ji Cao; Hong Zhu; Bo Yang; Xuejing Shao; Qiaojun He; Meidan Ying
Journal:  Autophagy       Date:  2020-09-22       Impact factor: 16.016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.